Associate Director/Director, Research & Development Program Management

Research Associate II/Senior Research Associate, Tumor Immunology 

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

A-Alpha Bio

A2 Biotherapeutics

AAVogen

ACELYRIN

AI Proteins

AIRNA Bio

ALX Oncology

AN2 Therapeutics

AOA Dx

ARTBIO

AUM BioTech

AVROBIO

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

Acepodia

Achieve Life Sciences

Acomhal Research

Acrivon Therapeutics

Actym Therapeutics, Inc.

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

Admera Health

Adverum Biotechnologies

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agastiya Biotech

Agena Bioscience

AiViva Biopharma

Ainnocence

AivoCode

Aixa Bio

Akero Therapeutics

Akita Biosciences

Akouos

Alamar Biosciences

Alector

Alida Biosciences

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Oncology

Alphabioregen

Alpine Immune Sciences

AltPep

Alterome Therapeutics

Altis Biosystems

Alto Neuroscience

Alumis

Alveo Technologies

Alveolus Bio

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AnHeart Therapeutics

Anagram Therapeutics

Ancora Biotech LLC

Andes

Andson Biotech

Anebulo Pharmaceuticals

Angiex

Angiocrine Bioscience

Anima Biotech

Ankyra

Annexon Biosciences

Anodyne Nanotech

Anokion

Ansa Biotechnologies

Antheia

Anthos Therapeutics

Apaxon Biotech LLC

Volastra Therapeutics is developing drugs that target a vulnerability of cancer cells - chromosomal instability, or CIN. CIN is present in 60-80% of cancers and is associated with poor survival in many patients.  By using their proprietary CINtech platform that incorporates cancer biology, data sciences and medicinal chemistry, Volastra is turning a deep biological understanding of CIN into life-saving therapies. The tools Volastra is using range from CIN CRISPR screen, CIN imaging and genomics to molecular structure-activity analysis. Volastra is initially focusing on two therapeutic approaches: synthetic lethality and immune activation, with programs in early development.

<p>Volastra Therapeutics is developing drugs that target a vulnerability of cancer cells - chromosomal instability, or CIN. CIN is present in 60-80% of cancers and is associated with poor survival in many patients.  By using their proprietary CINtech platform that incorporates cancer biology, data sciences and medicinal chemistry, Volastra is turning a deep biological understanding of CIN into life-saving therapies. The tools Volastra is using range from CIN CRISPR screen, CIN imaging and genomics to molecular structure-activity analysis. Volastra is initially focusing on two therapeutic approaches: synthetic lethality and immune activation, with programs in early development.</p>


Find a biotech startup job.